Relations between approved platinum drugs and non-coding RNAs in mesothelioma
| Autor: | Bernhard Biersack |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Mesothelioma
0301 basic medicine Bcl-2 B-cell lymphoma 2 endocrine system diseases DHA docosahexaenoic acid Biochemistry Carboplatin chemistry.chemical_compound 0302 clinical medicine RA retinoic acid TSA trichostatin A MPM malignant pleural mesothelioma Medicine HOTAIR HOX transcript antisense RNA SFN sulforaphane media_common MALAT1 metastasis-associated lung adenocarcinoma transcript 1 DIM 3 3′-diindolylmethane EGCG epigallocatechin-3-gallate MRP1 multidrug resistance protein 1 ABC ATP-binding cassette MicroRNA Long non-coding RNA Pemetrexed DMPM diffuse malignant peritoneal mesothelioma 030220 oncology & carcinogenesis SAHA suberoylanilide hydroxamic acid I3C indole-3-carbinol PEG polyethylene glycole EMT epithelial-mesenchymal transition medicine.drug Drug lcsh:QH426-470 PEITC phenethylisothiocyanate NaB sodium butyrate media_common.quotation_subject AKI acute kidney injury Anticancer drugs AKBA 3-acetyl-11-keto-β-boswellic acid Article TNBC triple-negative breast cancer 03 medical and health sciences NSCLC non-small cell lung cancer microRNA PDCD4 programmed cell death 4 Genetics Molecular Biology neoplasms DADS diallyl sulfide CAF cancer-associated fibroblast Cisplatin business.industry CBDCA cyclobutane-1 1-dicarboxylate Biochemistry (medical) medicine.disease PTEN phosphatase and tensin homolog Gemcitabine respiratory tract diseases lcsh:Genetics 030104 developmental biology chemistry Cancer research business |
| Zdroj: | Non-coding RNA Research, Vol 3, Iss 4, Pp 161-173 (2018) Non-coding RNA Research |
| ISSN: | 2468-0540 |
| Popis: | Malignant mesothelioma diseases feature an increasing risk due to their severe forms and their association with asbestos exposure. Platinum(II) complexes such as cisplatin and carboplatin are clinically approved for the therapy of mesothelioma often in combination with antimetabolites such as pemetrexed or gemcitabine. It was observed that pathogenic properties of mesothelioma cells and the response of mesothelioma tumors towards platinum-based drugs are strongly influenced by non-coding RNAs, in particular, by small microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). These non-coding RNAs controlled drug sensitivity and the development of tumor resistance towards platinum drugs. An overview of the interactions between platinum drugs and non-coding RNAs is given and the influence of non-coding RNAs on platinum drug efficacy in mesothelioma is discussed. Suitable non-coding RNA-modulating agents with potentially beneficial effects on cisplatin treatment of mesothelioma diseases are mentioned. The understanding of mesothelioma diseases concerning the interactions of non-coding RNAs and platinum drugs will optimize existing therapy schemes and pave the way to new treatment options in future. Keywords: MicroRNA, Long non-coding RNA, Mesothelioma, Cisplatin, Carboplatin, Anticancer drugs |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|